Immutep Limited (IMMP)
NASDAQ: IMMP · IEX Real-Time Price · USD
1.940
0.00 (0.00%)
At close: Jul 19, 2024, 4:00 PM
1.917
-0.023 (-1.19%)
Pre-market: Jul 22, 2024, 9:09 AM EDT
Immutep Employees
Immutep had 31 employees as of June 30, 2014. The number of employees increased by 1 or 3.33% compared to the previous year.
Employees
31
Change (1Y)
1
Growth (1Y)
3.33%
Revenue / Employee
$147,637
Profits / Employee
-$888,771
Market Cap
245.05M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Jun 30, 2014 | 31 | 1 | 3.33% |
| Jun 30, 2013 | 30 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| AVITA Medical | 207 |
| Utah Medical Products | 190 |
| Cibus | 183 |
| Senseonics Holdings | 132 |
| Mersana Therapeutics | 123 |
| Semler Scientific | 92 |
| Atai Life Sciences | 83 |
| Sera Prognostics | 57 |
IMMP News
- 10 days ago - Immutep Reports Positive Results in First Line Head and Neck Squamous Cell Carcinoma Patients with Negative PD-L1 Expression - GlobeNewsWire
- 19 days ago - Immutep Announces Details for Oral Presentation at ESMO Virtual Plenary Session and Webcast to Discuss Clinical Results - GlobeNewsWire
- 27 days ago - Immutep Signs Exclusive License Agreement with Cardiff University for Next Generation Anti-LAG-3 Molecules for Cancer - GlobeNewsWire
- 6 weeks ago - Immutep successfully completes institutional placement and institutional component of entitlement offer - GlobeNewsWire
- 7 weeks ago - Immutep Announces Clinical Collaboration with MSD to Evaluate Efti in Combination with KEYTRUDA® (pembrolizumab) in Pivotal Phase III Trial - GlobeNewsWire
- 2 months ago - Immutep Presents Data from Safety Lead-in Phase of AIPAC-003 at ESMO Breast 2024 - GlobeNewsWire
- 2 months ago - Positive Initial Clinical Data Reported from Immutep's Efti Combined with Radiotherapy and Checkpoint Inhibitor from Phase II Trial in Soft Tissue Sarcoma - GlobeNewsWire
- 3 months ago - Immutep Quarterly Activities Report Q3 FY24 - GlobeNewsWire